Your session is about to expire
← Back to Search
Celebrex and HO Study
N/A
Waitlist Available
Led By Adam Hart, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* All primary total hip replacements with Cementless Tri-lock BPS (Depuy, Warsaw, IN) with minimum 2 years follow up.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 mins
Awards & highlights
No Placebo-Only Group
Summary
The primary goal of this observational study is to demonstrate the incidence of heterotopic ossification (HO) in patients with cementless total hip joint replacement surgery over time and secondly, demonstrate the relationship between celecoxib and HO formation. Lastly, investigators will examine the relationship between HO and patient-reported outcome measures (PROMs).
Eligible Conditions
- Heterotopic Ossification
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 mins
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 mins
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of heterotopic ossification (HO) in patients with cementless total hip joint replacements over time.
Secondary study objectives
The association between celecoxib and patients with and without heterotopic ossification (HO) following cementless total hip joint replacements.
The association between heterotopic ossification (HO) and celecoxib and between HO and patient-reported outcome measures in patients with cementless total hip joint replacements.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Patients with and without HO before Celecoxib clinical pathwayExperimental Treatment0 Interventions
Patients with and without heterotopic ossification (HO) before the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2009-2012.
Group II: Patients with and without HO after Celecoxib clinical pathwayExperimental Treatment1 Intervention
Patients with and without heterotopic ossification (HO) after the clinical pathway was changed to include celecoxib following cementless total hip joint replacement surgery between periods 2013-2020.
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
471 Previous Clinical Trials
166,757 Total Patients Enrolled
Adam Hart, MDPrincipal InvestigatorResearch Institute of the McGill University Health Centre
1 Previous Clinical Trials
50 Total Patients Enrolled